Loading clinical trials...
Loading clinical trials...
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
Conditions
Interventions
KVD900 600 mg
KVD900 300 mg
Locations
71
United States
KalVista Investigative Site
Scottsdale, Arizona, United States
KalVista Investigative Site
Little Rock, Arkansas, United States
KalVista Investigative Site
San Diego, California, United States
KalVista Investigative Site
San Diego, California, United States
KalVista Investigative Site
Santa Monica, California, United States
KalVista Investigative Site
Centennial, Colorado, United States
Start Date
October 24, 2022
Primary Completion Date
June 30, 2026
Completion Date
June 30, 2026
Last Updated
February 18, 2026
NCT06960213
NCT07001280
NCT07298447
NCT06842823
NCT06573723
NCT07046806
Lead Sponsor
KalVista Pharmaceuticals, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions